As the multi-systemic components of COVID-19 emerge, parallel etiologies can be drawn between SARS-CoV-2 infection and radiation injuries. While some SARS-CoV-2-infected individuals present as asymptomatic, others exhibit mild symptoms that may include fever, cough, chills, and unusual symptoms like loss of taste and smell and reddening in the extremities (e.g., “COVID toes,” suggestive of microvessel damage). Still others alarm healthcare providers with extreme and rapid onset of high-risk indicators of mortality that include acute respiratory distress syndrome (ARDS), multi-organ hypercoagulation, hypoxia and cardiovascular damage. Researchers are quickly refocusing their science to address this enigmatic virus that seems to unveil itself in new ways without discrimination. As investigators begin to identify early markers of disease, identification of common threads with other pathologies may provide some clues. Interestingly, years of research in the field of radiation biology documents the complex multiorgan nature of another disease state that occurs after exposure to high doses of radiation: the acute radiation syndrome (ARS). Inflammation is a key common player in COVID-19 and ARS, and drives the multi-system damage that dramatically alters biological homeostasis. Both conditions initiate a cytokine storm, with similar pro-inflammatory molecules increased and other anti-inflammatory molecules decreased. These changes manifest in a variety of ways, with a demonstrably higher health impact in patients having underlying medical conditions. The potentially dramatic human impact of ARS has guided the science that has identified many biomarkers of radiation exposure, established medical management strategies for ARS, and led to the development of medical countermeasures for use in the event of a radiation public health emergency. These efforts can now be leveraged to help elucidate mechanisms of action of COVID-19 injuries. Furthermore, this intersection between COVID-19 and ARS may point to approaches that could accelerate the discovery of treatments for both.
The world is currently in the grip of a global pandemic. As of September 10, 2020, over 50 million cases of COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been reported worldwide. At the forefront of directing research activities focused on combating COVID-19 is the National Institute of Allergy and Infectious Diseases (NIAID) within the U.S. National Institutes of Health (NIH). In April 2020, the NIAID published the NIAID Strategic Plan for COVID-19 Research2 describing NIAID's efforts to better understand SARS-CoV-2 and to accelerate the development of safe biomedical tools. The plan is a well-defined document that focuses on four research priorities: improving fundamental knowledge of SARS-CoV-2 and COVID-19; supporting the development of diagnostics and assays; characterizing and testing therapeutics; and developing safe and effective vaccines against SARS-CoV-2. A detailed research plan for each priority area is described in the document.
The novelty of the 2019 novel coronavirus disease (COVID-19) is underscored by the fact that there are no FDA-approved or licensed therapeutics specific for corona-viruses. The traditional drug development pathway for therapeutics (and diagnostic tools) can be a years-long process with milestones that require extensive resources to achieve. However, the urgency of the COVID-19 pandemic emphasizes the need for rapid development and testing of promising therapeutic and diagnostic candidates. Approaches to accelerate the development process are being explored in other areas of science where overlapping trends can be investigated. Therapeutics developed for other clinical indications could potentially be repurposed to treat COVID-19; some of those possibilities are discussed in this review. Likewise, pathological features and manner of progression of other indications similar to COVID-19 could elucidate how to effectively mitigate and treat this disease. In this review, we describe observed parallels between COVID-19 and the biological effects of radiation injury that include immediate and long-term components: the acute radiation syndrome (ARS) and the delayed effects of acute radiation exposure (DEARE).
The Radiation and Nuclear Countermeasure Program (RNCP) within the NIAID is one such program in which the scientific work is relevant to the COVID-19 response. The RNCP was initiated in 2004, with the mission of supporting research to develop medical countermeasures to diagnose (biodosimetry) and treat radiation injuries leading to ARS and DEARE in the wake of a radiation public health emergency. The marked similarities between COVID-19 and radiation injuries described in this review have a major underpinning: the inflammatory response. Several products currently in development within the RNCP to treat radiation exposure operate by targeting inflammation that can lead to tissue damage. In fact, approaches developed to treat radiation-induced lung fibrosis and vascular damage merit investigating and are discussed here in the context of COVID-19.
Here we highlight some of the systems and immunological areas affected by both COVID-19 and acute radiation exposure, albeit to different levels. In both cases, the result is a systemic insult that can cause damage to many parts of the body, including the vascular system, lung, heart, kidneys, liver, gut, eyes and brain. Regardless of the target organ, the hyperactivation of the immunogenic pathways are at the heart of the body's response to overcome SARS-CoV-2 and acute radiation exposure (1 ). Cytokines are produced by a variety of immune cells (i.e., macrophages, B lymphocytes, T lymphocytes and mast) and non-immune cells (i.e., endothelial, fibroblasts and stromal). Under normal circumstances, cytokines have a short half-life and act as local mediators within a microenvironment; therefore, circulating cytokines in the blood are below the limit of detection of most commercially available assay kits (2 ). This complex communication network provides a healthy immune system with the proper signals to mount a proportionate response against an infectious agent or inflammatory stimuli. In other cases, the reaction is so strong that circulating cytokine levels surge, resulting in a “cytokine storm” (also called hypercytokinemia3) or an overaction of the immune system creating a generalized inflammatory response that can lead to systemic tissue damage. The cytokine storm is the nexus between SARS-CoV-2 infection and radiation exposure; both result in systemic inflammation that ravages the body (1, 3 ).
A wealth of early literature has described the cytokine storm syndrome (CSS) in COVID-19 patients (4–15 ). For example, in a study of 50 patients, expression levels of 14 of 48 cytokines studied were associated with disease severity and progression, with interferon (IFN)-γ-induced protein 10 and monocyte chemotactic protein-3 noted as excellent predictors of disease progression (16 ). Increases in granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) due to T-cell overactivation were also noted (17 ). Another retrospective study with 3,939 patients shows both mild and severe forms of COVID-19 disease resulting in changes in circulating leukocyte subsets and cytokine secretion (8 ). In particular, Vaninov et al. noted that persistent high levels of three cytokines (CXCL10, CCL7 and IL-1 receptor antagonist) were associated with increased viral load, loss of lung function, lung injury and a fatal outcome (12 ). Based on these kinds of findings of elevated levels of specific cytokines, in June 2020 the FDA issued an Emergency Use Authorization (EUA) for an in vitro diagnostic test based on measuring the circulating IL-6 levels in serum or plasma for the management of patients with COVID-194 (discussed in more detail below). However, emerging technologies measuring “cytokine signatures” demonstrate variability across subjects and highlight the need for the development of personalized treatments based on these data.
As observed with COVID-19, cytokines are also released by many cells after radiation exposure, including endothelial cells, fibroblasts, immune cells and parenchymal cells. The interplay and early activation of inflammatory reactions involving proteins in cytokine cascade, such as fibroblast growth factor (FGF), transforming growth factor (TGF), tumor necrosis factor (TNF-α), and interleukins (ILs) is thought to be responsible for DEARE. Cytokines and chemokines that attract immune cells and lead to inflammation include IL-1α and IL-6. Inflammatory cells cause numerous other changes to occur, such as cell death, promotion of fibrosis and swelling of the tissue. These cytokines are involved in both early and late reactions, like the major cytokines in the response of skin cells to ionizing radiation, and include IL-1, IL-6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, which can be pro-or anti-inflammatory depending on the tissue and context of release, and the chemokines IL-8 and eotaxin (18 ). Cytokines can be broadly grouped as pro-inflammatory cytokines such as TNF-α, IL-1α and β, IL-17; angiogenic/vascular endothelial growth factor (VEGF), TNF-α and FGF; anti-inflammatory IL-4, IL-10 and TGF-β; pro-fibrotic IL-6 and TGF-β; immune IL-2, IL-4 and IL-7; and hematopoietic CSF1, GM-CSF, IL-3 and EPO (19 ). Interestingly, persistence of inflammatory cytokines, chemokines and growth factors, such as TGF-β, IFN-γ, ET-1, IL-4, IL-13, lead to pulmonary fibrosis (20 ). Notably, IL-6, which appears to be a key player in the response to SARS-CoV-2, is altered after irradiation as well; however, its role in radiation-induced lung injury is still unclear (21 ).
In addition to the cytokine storm, dysregulation of the renin-angiotensin system (RAS) plays a critical role in the pathogenesis of COVID-19 (22 ) and radiation exposure. The RAS pathway, which regulates the body's fluid regulation system, is dependent on angiotensin converting enzyme (ACE) and ACE2. ACE regulates blood pressure, water, and sodium levels as well as inflammation, proliferation and vasoconstriction. ACE2, the target receptor of SARS-CoV-2, is involved in degrading AngII to produce Ang 1-7 and then further to angiotensin 1-5, which is the effector peptide (23 ). ACE2 can be found in a variety of organs (e.g., heart, kidney, adipose tissue, vascular smooth muscle cells, brain tissue, testis, gastrointestinal (GI) tract, etc.). Together ACE/ACE2 promote vasodilation to reduce blood pressure and maintain homeostasis of the RAS. ACE2 is expressed throughout the body, so it is no surprise that it plays many physiological roles, which extend beyond its ability to reduce blood pressure. These include cardiac and lung protection by ACE2. A mouse study by Imai et al. shows that AngII, upregulated by ACE, drives severe lung failure through the AT1a receptor while ACE2 and the AT2 receptors protect against lung injury. The group showed that exogenous recombinant human ACE2 reduces acute lung failure in ACE2 knockout and wild-type mice (24, 25 ), and impacts GI dysregulation and diabetic complications (26 ). As SARS-CoV-2 (27 ) binds ACE2, it is possible that ACE2 receptors are downregulated, causing an imbalance in the RAS (28 ).
Both cytokine and RAS disequilibria may have implications in the development of lung and other organ injuries for both COVID-19 (3, 22, 27 ) and ionizing radiation exposure (29, 30 ), although the interplay is complex and not completely understood. In general, SARS-CoV-2 infection (31 ) and ionizing radiation exposure (31 ) trigger pro-inflammatory cytokines (e.g., IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGF-β, etc.). In the case of COVID-19, the lung is the most prevalent initial target and, in some cases, the injury progresses from pneumonitis (32, 33 ) to acute respiratory distress syndrome (ARDS). This heightened chronic inflammatory response creates a pro-fibrotic environment that yields long-term fibrosis followed by organ dysfunction. Similarly, exposure to radiation can also result in lung fibrosis (34–36 ) as well as injury to other organs (37–39 ).
The vasculature is also targeted by SARS-CoV-2, as evidenced by the prevalence of systemic thrombotic events (40 ), endotheliitis (endothelial inflammation) (41 ) and “COVID toes” (suggesting dysfunction of microvessels in the extremities) (42, 43 ). The virus has been shown to directly infect endothelial cells (41 ), and their subsequent dysregulation likely explains the many vascular coagulopathies and thromboses that have been noted in COVID-19 patients. Recently, Zamboni (44 ) described COVID-19 as a vascular disease, with the endothelial cell emerging as a potent target for SARS-CoV-2, while the endothelium is called “the lynchpin” of COVID-19 pathogenesis, orchestrating the cytokine storm and damage to multiple organs (45 ). In severe cases, this dysfunction has led to strokes (46 ) and other cardiovascular involvement (47 ). Similarly, acute radiation exposure leads to vascular injury (48 ) by way of apoptosis and senescence of endothelial cells as well as via an increase in cell adhesion molecules (49 ) and dysregulation of coagulation homeostasis (50 ).
Another common target of SARS-CoV-2 and acute radiation exposure is the pyroptosis pathway or caspase-1dependent programmed cell death of eukaryotic cells. Pyroptosis is a mechanism by which the body's innate immune system clears pathogens and promotes an adaptive immune response. Caspase-1 initiates inflammation that results in the formation of plasma-membrane pores in pathogen-infected cells, enabling water to enter, causing swelling and osmotic lysis. In addition, caspase-1 promotes cleavage of chromosomal DNA and nuclear condensation. Caspase-1 is activated by Toll-like receptors (TLRs) and NOD-like receptors (NLRs) present on immune cells, such as macrophages or epithelial cells, which sense extracellular and intracellular danger signals produced by pathogens or tissue injury. This cellular communication network results in an inflammatory cascade initiated by NF-κB, mitogen-activated protein kinase (MAPK)- and interferon-regulatory factor (IRF)- dependent pathways, activating IFN-α/β, TNF-α/β, IL-12, IL-6, IL-8 and pro-IL-1β. The pyroptosis pathway is also implicated in immune cell death (e.g., in the spleen) after acute radiation exposure (51, 52 ). Furthermore, the NF-κB/TNF-α signaling pathway is also activated in response to ionizing radiation, resulting in a similar cytokine cascade. In fact, a recently published study showed that pyroptosis may play a role in radiation-induced lung inflammation and fibrosis (53 ).
Biomarkers in Pathophysiology of COVID-19 and Radiation Injury
There is a remarkable similarity in the pattern of biomarker response to SARS-CoV-2 infection and radiation exposure. Significant changes in hematological, chemical, inflammatory and immune biomarkers are seen in COVID-19 and in irradiated patients. Although the insult (infection or acute radiation exposure) is vastly different, the ensuing pathologies converge to multiorgan dysfunction (MOD), resulting in multiorgan failure (MOF) and mortality. Biomarkers unique to each insult, such as smell dysfunction for COVID-19, or cytogenetic, genomic or metabolomic approaches for radiation biodosimetry are not discussed here.
The classical approach of hematology has emerged as a valuable tool in predicting outcome as well as stratifying and management of COVID-19 patients (54–59 ). For example, a retrospective analysis compared hemocyte counts (neutrophils, lymphocytes and platelets; or “NLP score”) and found a strong correlation between NLP score and COVID-19 disease progression, while another published study noted lymphocyte decrease associated with COVID-19 severity (60, 61 ). Furthermore, Chen et al. conducted a retrospective study on 548 patients and noted that the counts of lymphocytes, T-cell subsets, eosinophils and platelets decreased markedly, especially in severe/critical and fatal patients. Increased neutrophil count and neutrophil-to-lymphocyte ratio were predominant in severe/critical cases or non-survivors (61 ). From separate studies, it was observed that an increase in the neutrophil-to-lymphocyte ratio (NLR) is an early warning signal for severe COVID-19 (59, 62, 63 ). These data are further supported by findings from a published study of 75 patients from Suzhuo, China with confirmed COVID-19 infection; common COVID-19 abnormal hematological indexes on admission included hyperfibrinogenemia, lymphopenia, elevation of D-dimer, and leukopenia, which were significantly different between the mild/moderate and severe COVID-19 groups. Furthermore, the dynamic change of NLR and D-dimer level can distinguish severe COVID-19 cases from the mild/moderate (64 ).
Hematological data could be further refined to interrogate a single cell population (such as lymphocytes or platelets) that yielded significant correlation with COVID-19 progression and severity. A meta-analysis of 3,099 patients from 24 different studies showed that patients who did not fare well had low lymphocyte counts (mean difference of – 361.06/µl) compared to patients who had good outcomes (65 ). Other researchers have also reported lymphopenia as a key biomarker in COVID-19 patients (66–68 ); Terpos et al. (68 ) referred to lymphopenia as “a cardinal laboratory finding, with prognostic potential,” urging for the need for longitudinal evaluation of parameters to follow the dynamics of the disease progression. Thrombocytopenia is also commonly noted among patients hospitalized with COVID-19 and a low platelet count is associated with higher mortality (57, 69–74 ). It is hypothesized that SARS-CoV-2 infects both bone marrow cells and platelets via the CD13 receptor, inducing growth inhibition and apoptosis. This entry disrupts hematopoiesis, resulting in thrombocytopenia. Another cause of thrombocytopenia is attributed to lung injury due to activation, aggregation, and retention of platelets in the lung. The formation of thrombus at the site of lung injury leads to decreased platelet production and increased consumption (75, 76 ). Interestingly, in most cases the platelet decreases did not reach a level where spontaneous bleeding occurred.
As seen with COVID-19 patients, radiation exposure also results in profound hematological perturbations in humans as well as irradiated animal models, characterized by granulocytopenia, lymphopenia and thrombocytopenia (77–81 ). Unlike COVID-19, significant decreases in neutrophils, in addition to other cytopenias, is a hallmark of ARS (82 ). The SEARCH (System for Evaluation and Archiving of Radiation accidents based on Case Histories) (82 ) database contains 824 clinical cases from 81 radiation accidents in 19 countries and allows detailed analysis of the time course of ARS, with the intention to study all medical aspects of ARS and to derive medical treatment protocols for radiation accident victims (MEdical TREatment ProtocOLs; METREPOL) (83 ). The hematopoietic syndrome can be characterized by granulocyte count kinetics (84 ). The Radiation Emergency Medical Management (REMM)5 website provides guidance on triaging radiation accident victims based on lymphocyte depletion kinetics. The kinetics of lymphocyte depletion have been shown to be directly related to the absorbed radiation dose from 0.5 to 10 Gy (85–87 ). Furthermore, the ratio of neutrophil to lymphocyte has been employed to determine the radiation dose exposure (88–90 ). Interestingly, platelet depletion alone has not been used to determine radiation dose, although thrombocytopenia correlates directly with radiation dose and platelet utilization at sites of active bleeding.
Patients with moderate and severe COVID-19 showed significant increase in levels of serum amyloid A (SSA), C-reactive protein (CRP) which positively correlated to COVID-19 pneumonia (24 ), and serum albumin (ALB) levels (P < 0.05) (62 ). Radiation also induces increases in the serum and urine proteome. CRP and serum amylase are commonly elevated after radiation exposure (91–93 ). In the criticality accident at Tokaimura, all three patients presented with elevated serum amylase (94 ). CRP levels were reported to correlate with clinical outcome in patients exposed to radiation during the Chernobyl nuclear accident (95 ). From a published study that identified 260 radiation-responsive proteins (96 ), Partridge et al. (97 ) narrowed the panel to IL-6, IL-1β, TNF-α and TGF-β levels as being strongly correlated to irradiation, with IL-6 emerging as the best marker for COVID-19 and acute radiation exposure.
Electrolyte imbalance with reduced potassium, calcium, chloride and sodium is observed in patients with COVID-19 (72, 76, 98 ). Pooled analysis of data on serum electrolytes confirms that hyponatremia, hypokalemia and hypocalcemia are associated with COVID-19 severity; however, the authors cautioned that additional information such as calcium concentrations, serum albumin levels and the patients' fluid status is necessary for accurate interpretation of laboratory findings (99 ). Interestingly, the authors draw a correlation between electrolyte imbalance and progression of COVID-19 disease and MOF. SARS-CoV-2 binds to its host receptor, ACE2, and reduces ACE2 expression, leading to increased angiotensin II, which can cause increased potassium excretion by the kidneys resulting in hypokalemia, while plasma angiotensin II is purported to be a mediator of ARDS and ensuing MOF seen in a significant number of COVID-19 patients (100 ). Another cause of electrolyte loss in COVID-19 patients is attributed to GI causes such as diarrhea and emesis (101 ). The U.S. Centers for Disease Control (CDC) has described a similar electrolyte imbalance, accompanied by diarrhea and emesis, due to damage and disruption of the intestine after radiation exposure (102, 103 ).
Lymphocyte counts provide a rapid snapshot of the prognosis for patients with COVID-19. Delving into the lymphocyte subsets provides a clearer understanding of the patient's immune status, with both diagnostic and prognostic value (104 ). In a 103-patient study, a significant decrease in T-cell populations were reported. In particular, the CD3+, CD4+, CD8+ and NK cell counts dropped, with the CD4+/CD8+ ratio increased in COVID-19 patients compared to healthy controls (105 ). In other published studies, a correlation was noted between the severity of disease and reduction in T-cell subunits (61, 66 ) as well as decreases in B-cell numbers (106 ).
Persistent changes in the immune system after radiation exposure are manifested as abnormalities in the lymphoid populations and function (107 ). Radiation studies have documented immediate changes in T-cell subsets (108 ) and B cells (109 ) linked to radiation dose. In particular, depletion of CD8+ cells has been correlated with absorbed radiation at low doses (110 ). In atomic bomb (A-bomb) survivors, a decrease in CD4 helper T-cell populations, attenuated T-cell function, as well as an increase in B-cell populations, which could drive long-term inflammation. Radiation dose-dependent reduction in CD4+ cell population has also been reported (111, 112 ). While these metrics are not used to monitor disease progression, they are indications of the continued immune dysfunction observed in patients after radiation exposure (113 ).
Histological analysis of COVID-19 has shown that the presence of SARS-CoV-2 within endothelial cells was associated with clusters of inflammatory cells, suggesting that infection initiates endotheliitis throughout the entire human body, leading to systemic macro and microcirculatory dysfunction in vascular beds (44 ). VEGF-D was noted as an indirect procoagulant biomarker of COVID-19 progression (114 ) and angiopoietin-2 (a marker for endothelial activation), was associated with microvascular dysfunction (115 ). Vascular abnormalities such as vascular thickening, detected by thoracic computed tomography (CT), was reported to be significantly associated with COVID-19, when compared to non–COVID-19 pneumonia (59% versus 22%, P < 0.001) (116 ). Ultimately, endotheliopathy converges with COVID-19-associated coagulopathies; a recently published study showed significant elevation in markers of endothelial cell and platelet activation with mortality strongly correlated to von Willebrand factor (VWF) antigen and plasma thrombomodulin (117 ).
Vascular dysfunction resulting from radiation exposure has also been reported. Of the 28 people who died within 98 days of the Chernobyl criticality incident, deaths were attributed to skin, GI and lung reactions, but most deaths were characterized by circulatory problems, with a high incidence of edema and focal hemorrhages (118 ). After the Tokaimura Nuclear Plant accident in Tokai, Japan, Akashi discussed the possible role of inflammation and hemorrhage in radiation-induced MOF. In a review of 110 cases histories of radiation accidents spanning 1945 through 2000, the authors analyzed MOF after total-body irradiation (TBI) and stated that “. . .symptomatology of organ system involvement could be traced not only to the pathophysiology of the rapidly turning over cell renewal systems but – of equal or more importance – to the vascular system and specifically, to the endothelial components.” (119 ). The primary target of radiation injury to the vasculature is the endothelial cell. The acute phase of damage occurs within hours to weeks postirradiation, and is characterized by endothelial swelling, vascular permeability and edema, lymphocyte adhesion and infiltration, and apoptosis (52 ). Radiation-induced vascular biomarkers include inflammatory signals, endothelial activation and adhesion markers, and prothrombic markers (48, 120, 121 ), similar to those reported for COVID-19.
As of September 10, 2020, the FDA has authorized EUAs for more than 150 individual molecular diagnostic tests for SARS-CoV-2. As a sampling, from February 4, 2020 to June 18, 2020, a total of 85 tests received EUA authorization, which included 37 tests for detection of nucleic acids from SARS-CoV-2 and one antigen diagnostic test, with required conditions for manufacturers and authorized laboratories.6 Similarly, as of mid-June 2020, the FDA had authorized more than 20 serology biomarker tests, with the caveat to “always refer to the complete instructions for use to put these estimates into the proper context and to understand how to use and interpret these tests.” On June 2, 2020, the FDA authorized the only in vitro diagnostic test for the management of patients with COVID-19, which is based on measuring the circulating IL-6 levels in these patients. In stark contrast, no radiation biodosimetry test has been cleared/authorized by the FDA.
As more information becomes available, it is increasingly apparent that COVID-19 is not just a pulmonary affliction, but a multi-organ disease. Curiously, many symptoms as well as underlying pathogenesis in this multi-organ injury caused by SARS-CoV-2 are similar to the multi-organ injury caused by acute ionizing radiation exposure. In a nuclear incident, a person's entire body may be exposed to large doses of damaging ionizing radiation, while SARS-CoV-2 can only infect cells co-expressing angiotensin-converting enzyme 2 and transmembrane serine protease 2 (TMPRSS2). The presence of these proteins on a wide variety of cell types throughout the body such as airway epithelial cells, alveolar epithelial cells, lung macrophages and vascular endothelial cells (122, 123 ), absorptive enterocytes of the ileum and colon (124 ), explains the widespread damage caused by the infection (124 ). Indeed, SARS-CoV-2 RNA has been detected in sputum, nasal swabs, saliva, feces, blood, tears, urine and cerebrospinal fluid (125–128 ). Despite the differences in the initial cause of injury, systemic inflammation and coagulopathy, including disseminated intravascular coagulation (DIC) are hallmarks of both COVID-19 (123, 129–131 ) and acute radiation injury, with pyroptosis (51, 53, 131, 132 ) and neutrophil extracellular traps (133, 134 ) found in both. As noted in COVID-19 patients, hematopoietic ARS patients develop lymphopenia, thrombocytopenia and neutropenia due to bone marrow damage (135 ), possibly further contributing to multi-organ damage and failure. These disease processes found in both COVID-19 and acute and delayed radiation syndromes may directly cause or further exacerbate injury and pathogenesis in multiple organ systems (Fig. 1). In fact, multi-system inflammatory syndrome in children with COVID-19 has recently been described and affects a wide range of organs and systems (136 ).
Pulmonary disease and symptoms are the most common presentation of COVID-19 and respiratory failure is the most common cause of death in those with COVID-19 disease (98, 137 ), whereas lung damage in irradiated patients is a later effect (compared to hematological and GI manifestations). Nonetheless, these injuries can also be severe and lead to death (138, 139 ). Pneumonitis and subsequent drop in blood oxygen levels are seen in COVID-19 patients (98, 123, 140 ), as well as after irradiation, which often progresses to pulmonary fibrosis (36, 139 ). As with lung damage seen in COVID-19 patients, fibrosis was also seen in long-term follow-up of Middle East respiratory syndrome (MERS) patients (141 ). An increase in local neutrophils, cytokines and other immune factors is seen in COVID-19 patients with lung damage (32, 33 ), and also in patients and animal models of acute radiation exposure (34–36 ). These factors may also contribute to pneumonitis and provide further support to the hypothesis that lung injury seen in COVID–19 patients may progress to lung fibrosis.
While pulmonary symptoms are the most common in COVID-19 patients, GI symptoms are also common. Nausea, vomiting and diarrhea are all common symptoms in both COVID-19 and irradiated patients. In one published study of 651 patients in China, it was found that 11.4% of patients experienced at least one GI symptom (142 ) while in another study, 5% and 3.8% of hospitalized COVID-19 patients experienced nausea/vomiting and diarrhea, respectively (143 ). Additionally, SARS-CoV-2 RNA is often found in stool samples of patients with and without GI symptoms (144 ), which is not surprising given that ACE2 is expressed throughout the intestines and co-expressed with TMPRSS2 in enterocytes in the ileum and colon (124 ). In addition, SARS-CoV-2 was recently found to infect enterocytes in vitro (145 ). The intestinal damage and symptoms seen in COVID-19 do not appear to be as extreme as those observed in GI-ARS, where crypt stem cells die, leading to loss of GI function and integrity, causing not only nausea, vomiting and diarrhea, but also hemorrhage, endotoxemia, bacterial infection and even death (34, 146 ). However, the involvement of the gut microbiota should not be overlooked in either disease process. While the effect of SARS-CoV-2 infection on the gut microbiome is not yet known, a healthy gut microbiome may have contributed to a successful, but not overly-inflammatory immune response and expedited recovery with other respiratory diseases (147 ). Interestingly, fecal microbiota transplants have been shown to increase survival in a lethal irradiation mouse model (148 ).
Another organ of concern is the heart. Though the coagulopathy seen in both COVID-19 and ARS may contribute to cardiomyopathy and circulatory failure, direct cardiac tissue remodeling is also seen in both disease processes. Cardiac ischemia, inflammation, fibrosis and wall thickening have been noted in COVID-19 patients (149, 150 ) and after irradiation, though dependent upon dose and time after irradiation (151, 152 ). SARS-CoV-2 infection and radiation both increase risk of myocardial infarction, with one study from China reporting that 7% of case fatalities had only myocardial damage and circulatory failure without respiratory failure (137 ). Studies of A-bomb survivors have shown that cardiovascular disease risk increases 14% per Gy of exposure (153 ). The short- and long-term effects of cardiac damage from both disease processes is a concern.
Additionally, symptoms indicating damage to the central nervous system have been observed in patients with COVID-19 and those with ARS. Headache, disorientation, cognitive dysfunction, ataxia, seizures, unconsciousness, as well as other symptoms have been reported in patients who received lethal high-dose radiation (135 ) and in adult and juvenile COVID-19 patients (126, 154, 155 ). Radiation causes vascular damage and inflammation leading to hemorrhage and edema (156 ) and can increase risk of stroke (157 ). Similarly, brain damage in COVID-19 could be due to systemic inflammatory response and coagulopathy, leading to stroke and other issues (158 ), or may be directly due to infection of brain tissue, as SARS-CoV-2 RNA has been found in cerebrospinal fluid and in brain tissue after autopsy (159 ). Brain damage due to SARS-CoV-2 infection or irradiation can initiate or exacerbate injury to other organs, including respiratory or circulatory failure (159 ). Additionally, there is some evidence that radiation exposure may cause long-term psychological issues (160 ), and given the similarities between radiation-induced central nervous system inflammation and coagulopathy and that seen in COVID-19, long-term neurological and psychological effects may be forthcoming.
Several published studies have outlined the cutaneous manifestations of COVID-19. These symptoms appear at different time points of the disease progression, either at onset of disease or after hospitalization (161 ), and depend on the severity (mild or severe) of the infection (162–164 ). The most common symptoms identified in patients with mild infections are chilblain-like eruptions (i.e., COVID fingers or toes), and petechiae/purpuric rashes, while patients with severe infections experience symptoms such as acro-ischemia with finger and toe cyanosis, cutaneous bullae, dry gangrene, chickenpox-like rash and maculopapular lesions (162 ). Like COVID-19, cutaneous manifestations from ARS depend on the timepoint and severity of exposure often assessed using a graded scale set forth by the National Cancer Institute (165 ). The most common symptoms are also the least severe, i.e., acute radiation dermatitis and mild erythema, and are seen in patients exposed to low-dose radiation. These complications usually present within 90 days of radiation exposure (165 ). Radiation-induced telangiectasias, keratoses, ulcers, hemangiomas, splinter hemorrhages in the distal nail bed, lentiginous hyperpigmentation and severe subcutaneous fibrosis may also occur. High-dose radiation exposure leads to severe symptoms such as moist desquamation and ulceration (165 ). Of note, these or similar injuries may occur in the oral epithelium in both COVID-19 (166, 167 ), and after radiation exposure (168 ). In comparing cutaneous manifestations related to COVID-19 and ARS, the symptoms associated with ARS are more severe and long lasting. Delayed effects can be seen months to years postirradiation, while lesions due to COVID-19 infection appear to heal more quickly, usually within a few days (161, 169 ). On the other hand, vascular complications associated with COVID-19 infection closely resemble mild radiation burns seen in patients that have been exposed to mild (non-lethal) doses of radiation. In both COVID-19 and mild radiation cutaneous injury, vascular injury may be further contributing to the skin injury, and damage to the vasculature in the upper layers of the skin may be involved (162, 163, 169 ).
Other symptomatic overlaps between COVID-19 and radiation exposure include: acute kidney injury (72, 170–172 ), whether coagulopathy-related or direct, as renal tubule cells are a potential target for SARS-CoV-2 (173 ); liver injury, though more severe and possibly fibrotic in radiation hepatitis (174 ) compared to the usually mild elevation of aspartate aminotransferase and alanine aminotransferase levels seen in 14–53% of COVID-19 patients (175 ); and conjunctivitis (127, 176, 177 ), an immediate effect of radiation with possible long-term effects including macular degeneration and cataracts (178, 179 ). Fertility issues have been seen in irradiated individuals, and there is concern regarding male fertility in COVID-19 patients as well, as ACE2 receptors are also expressed in the testis, and some male patients have reported scrotal discomfort. Nonetheless, SARS-CoV-2 has yet to be found in semen, and this disease may still be too new to identify fertility issues (180 ). High rates of androgenetic alopecia in hospitalized COVID-19 patients have been documented, leading to the hypothesis that the use of anti-androgen therapy (flutamide) may be a possible treatment for COVID-19 patients (181 ).
Radiation-induced coagulopathies (RIC) are part of the continuum of the irradiation sequalae (134, 182, 183 ), with parallels to DIC. Hemorrhage, a hallmark of DIC, was reported in 60% of the mortalities in the A-bomb-exposed population, accompanied by petechial lesions and thrombocytopenia (184 ), and was also observed after (184 ), as well as other radiation accidents (185, 186 ). Prevalence of prolonged clot formation times, increased levels of thrombin-antithrombin III (TAT) complex and increased circulating nucleosome/histone (cNH) levels were noted in blood from irradiated clinical samples (134 ). D-dimer has not been reported in any of the radiation-related coagulopathy studies, but other metrics used to predict coagulopathy for COVID-19 are similar to RIC. Though in many systems radiation damage is much more severe and chronic, overall, the similarities noted thus far between COVID-19 and ARS/DEARE may provide insight into the late effects of COVID-19, as well as shed light on possible targets for diagnostics, prognostic markers and therapeutics.
As noted, there are clear parallels between radiation exposure, which is known to act systemically to cause damage, and COVID-19, which has been implicated in organ damage ranging from the lung and GI tract to the heart, brain, kidney and vasculature. In fact, the characteristics of radiation-induced pneumonitis are similar to SARS-CoV-2 interstitial pneumonia (187 ). Therefore, it is not surprising that there are a number of treatments for radiation exposure under development that could prove to be efficacious for COVID-19. Because it is not possible to “fight” radiation in a conventional sense, in the way that it is possible to develop approaches directly targeting a pathogen, researchers have relied instead on modifying the host response to injury, to identify therapies to address damage caused by exposure to radiation. In many cases, these approaches have worked by harnessing the body's innate immunity, which is often dysregulated by radiation exposure. These treatments fall into several general categories, which include anti-oxidants, anti-inflammatories, antibiotics, anti-fibrotics, growth factors, cellular therapies, and products that target the vasculature or the RAS. Especially important to emphasize is the ability to repurpose these kinds of established drugs, some of which are already in clinical use, to expedite their use in patients with SARS-Cov-2 infection. These varied approaches will be considered separately below, according to their mechanisms of action.
COVID-19 is characterized by damage to the lung and vasculature, reducing blood oxygenation. In a review of the effects of erythropoietin (EPO), Ehrenreich et al. (188 ) noted that EPO acts on tissues beyond erythropoiesis; these effects could be brought to bear in fighting SARS-CoV-2 pathology. EPO is produced in the body in response to low oxygen levels, and in the short term, binds to receptors in the brain stem to improve mechanical ventilation. EPO also acts on airways and lung vasculature to reduce inflammation and promote vascularization and has been shown clinically to be neuroprotective. Although at this writing, no trials have been started, a randomized placebo-controlled trial for proof-of-concept has been proposed. EPO has also been shown to accelerate the expansion of erythroid progenitors in mouse irradiation models (189, 190 ). Galal et al. (191 ) described the effects of EPO beyond erythropoiesis, through the reduction of oxidative stress via upregulation of anti-inflammatory receptors. These activities point to possible treatments to reduce inflammation contributing to radiation-induced GI, lung, or kidney injury.
Leukine® (sargramostim or granulocyte-macrophage colony-stimulating factor, GM-CSF; Partner Therapeutics Inc., Lexington, MA) is one of three leukocyte growth factors approved by the U.S. FDA for treatment of ARS (192 ). Lang et al. (193 ) noted that, just as immune system stimulation can either help the body fight a viral infection or produce a deleterious inflammatory response, administration or inhibition of GM-CSF may be useful therapies for COVID-19. Lung macrophages depend on alveolar GM-CSF production for their maintenance, and GM-CSF administration could provide protection against viral infection in the early stages of ARDS and promote tissue repair. At this writing, sargramostim is being proposed as a therapeutic against COVID-19 in three trials7 (NCT04400929, NCT04326920, NCT04411680). As for deleterious effects, GM-CSF can exacerbate the inflammatory response, driving lung pathologies such as those resulting from COVID-19. In this case, GM-CSF inhibition could reduce expression of the pro-inflammatory cytokines IL-1, IL-6 and TNF, providing a multi-pronged approach to dampen an overstimulated immune system. Monoclonal antibody treatments targeting GM-CSF or GM-CSF receptor that are ongoing include: otilimab (NCT04376684), gimsilumab (NCT04351243), lenzilumab (NCT04351152), TJM2 (NCT04341116) and mavrilimumab (NCT04397497, NCT04399980, NCT04447469). Namilumab is being used in the clinic in an expanded access program. Patients receiving treatment in these experimental protocols will need to be monitored carefully because of the role that GM-CSF plays in immunological homeostasis. In addition, it would appear that the timing of these kinds of growth factor interventions is critical to their potential efficacy.
Radiation-induced damage is characterized by increases in reactive oxygen species (ROS) and oxidative stress (194–196 ). These increases, and the resulting inflammatory response, can damage other sensitive tissues (197–200 ). The antioxidant N-acetyl cysteine (NAC) has been shown to mitigate radiation-induced damage to the GI tract and improve 10- and 30-day survival in mice receiving total-abdominal irradiation (201 ). NAC also decreased out-of-field bone marrow damage and ROS levels, suggesting that bone marrow damage contributes to some of the radiation-induced GI injury. Because of similar patterns of tissue damage, Corry et al. hypothesized that COVID-19-induced damage to the lung could also be ameliorated by NAC treatment (202 ). This hypothesis was further supported by an earlier finding that NAC treatment of patients with acute lung injury and ARDS resulted in reduced mortality (203 ). Currently, there are several ongoing national clinical trials to address the possible benefit of NAC treatment in COVID-19 patients (NCT04374461, NCT04419025, NCT04370288 and NCT04279197).
Another compound under investigation for COVID-19 is the histamine H2-receptor antagonist famotidine. Typically used to treat acid reflux and heartburn, the drug is also known to have antioxidant activity (204 ). Although an unlikely candidate to treat viral disease, famotidine first came to the attention of researchers interested in repurposing already-licensed products (205 ). Generic and off-patent drugs were of particular interest because of their safety and affordability, supported by extensive data in humans (206 ). In addition, in silico analysis suggested that the drug could be useful as a therapeutic alternative in COVID-19 (207 ). Clinicians have noted that hospitalized patients taking the drug for other medical indications appeared to recuperate from COVID-19 better than those who did not take the drug (208 ). A review of over 6,000 patient records suggested that famotidine use led to a death rate of ∼14%, compared to 27% for those who had not taken famotidine. This finding was further supported by a retrospective analysis of COVID-19 patients who received the drug within 24 h of hospital admission, which showed that its use reduced the risk of intubation or death (209 ). One suggested mechanism of action of famotidine is a direct action on the receptor, leading to improved mast cell regulation (210 ). Additional, prospective clinical trials to look at the efficacy of the drug in COVID-19 patients are underway (NCT04370262, NCT04389567). A recently published article has suggested that famotidine is ineffective; however, the authors state that “We're not challenging that famotidine might help. We're saying that the mechanism of action is not antiviral”.8 This is consistent with the primary proposed antioxidant mechanism of action.
Radiation researchers have also sought to understand the protective effects of famotidine administration, with regards to limitation of DNA damage and cellular protection. With studies performed in vivo, in both pre-clinical irradiation models as well as in patients undergoing radiotherapy, the potential benefits of the drug have been demonstrated. Famotidine was found to be radioprotective in mice that were administered the drug prior to irradiation, as assessed by micronuclei formation in cells of the bone marrow (211, 212 ). Pre-clinical work with mouse leukocytes collected from irradiated animals documented consistent outcomes, with reductions in DNA damage in animals treated with famotidine prior to irradiation (213 ). Famotidine also significantly reduced lymphocytopenia in prostate cancer patients who received the drug a few hours prior to undergoing radiotherapy (214 ). In another study, prostate cancer patients given twice-daily oral doses of famotidine during their radiotherapy led to a reduction in radiation-induced injury to the normal rectal tissue (215 ). These clinical findings in cancer patients were based on earlier work using peripheral blood samples taken from normal healthy volunteers (216 ). In those studies, blood was irradiated ex vivo in the presence or absence of vitamin C and famotidine. Comet assay results suggested that the presence of famotidine was protective for radiation-induced apoptosis, with an estimated dose reduction factor of 1.5. The protective effects of the drug noted above suggest the drug may have an antioxidant effect and ability to scavenge free radicals, a mechanism that would justify clinical use of the drug for COVID-19.
Severe COVID-19 is characterized by a cytokine storm, indicative of an overactive immune response to the infection (217 ). Because elevated levels of pro-inflammatory cytokines are associated with high morbidity and mortality, various approaches to modulate the inflammatory response have been proposed. Specifically, COVID-19 results in elevated levels of serum IL-6 (217 ). The IL-6 receptor antagonist, tocilizumab (Actemra®, Genentech, San Francisco, CA), indicated for rheumatoid arthritis, has also been proposed to ameliorate radiation-induced tissue damage, and has shown efficacy in diminishing the cytokine storm resulting from cancer immunotherapy (218 ). In early published clinical studies to assess the potential impact of tocilizumab treatment in COVID-19, Somers et al. (219 ) performed a single-site trial of the drug in 154 COVID-19 patients on mechanical ventilation. Treatments resulted in a lower hazard of death, although the rate of superinfections increased. Antinori et al. (220 ) noted the risk of a secondary Candida infection from tocilizumab treatment, and therefore suggested that the drug only be used in well-designed clinical trials. Currently, a tocilizumab treatment arm has been included as part of the University of Oxford's Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial,9 the results of which have not been made available at the time of this writing. In a study looking at the effect of the drug in critically ill patients, treatment led to improved oxygenation and blood counts (221 ). In addition, another anti-IL-6 receptor antibody, sarilumab (Kevzara®; Regeneron Pharmaceuticals Inc., Tarrytown, NY and Sanofi, Paris, France) is also under clinical consideration in more than 10 registered trials as a treatment for late-stage COVID-19 patients.
Dexamethasone is a generic corticosteroid drug, which is licensed for a broad range of indications including arthritis, allergic reactions and immune system disorders. Dexamethasone has been shown to reduce multi-organ damage, including lung injury, in rats that have been exposed to localized radiation (222 ). In non-human primate (NHP) models of radiation-induced lung injury, dexamethasone has been used as a component of the medical management, where it is given when there is an increase in the non-sedated respiratory rate, which suggests respiratory distress (138, 223, 224 ). This use of the drug is similar to its clinical use for dyspnea (225 ). In these NHP studies, dexamethasone treatment reduced the elevated respiratory rate, lung density, pleural effusion and pneumonitis, leading to improved outcomes. Dexamethasone treatment has also been included as an arm in the RECOVERY trial (226 ), where its use has been shown to reduce COVID-19 mortality from 40.7% to 29% among patients who required invasive mechanical ventilation, but did not appear to confer a benefit to hospitalized patients who received only oxygen. These data suggest that corticosteroid treatment may only be effective if the immune system is overstimulated to the extent that it is causing significant harm. The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group performed a meta-analysis of seven randomized trials and concluded that systemic corticosteroids reduced 28-day all-cause mortality (227 ). Another treatment that has been shown to improve survival in a mouse model of radiation-induced lung injury is BIO 300 (Humanetics Corp., Edina, MN), which is a nanosuspension of the soy isoflavonoid, genistein. In mice, BIO 300 administration improved survival and reduced other morbidities caused by lung irradiation (228 ). Although genistein has antiviral activity (229–231 ), it may also be useful to prevent radiation-induced lung damage. Genistein is thought to act through inactivation of NF-κB (232 ), and since NF-κB inhibition has been shown to reduce inflammation in a mouse model of COVID-19, it could be effective in treating lung complications caused by SARS-CoV-2 infection. Humanetics has announced initiation of a clinical trial in discharged COVID-19 patients, to determine if treatment with the oral BIO 300 product can reduce late lung fibrosis and improve quality of life in patients who are recovering from the infection (NCT04482595).
Given that the autoimmune disease, rheumatoid arthritis (RA) is caused by an overactive immune response that targets normal joint tissue, it is not surprising that approaches that have shown benefit in RA are being considered for COVID-19. For example, anakinra (Kineret®; Swedish Orphan Biovitrum AB, Stockholm, Sweden), a specific IL-1 receptor antagonist, has been proposed as a possible treatment. Similarly, anakinra has been reported to reduce vascular inflammation in a mouse model of radiation exposure (233 ). In that study, administration of the drug for two weeks postirradiation reduced the expression of inflammatory mediators such as pro-caspase and caspase-1. In an early case report from Italy, clinicians described a critically ill patient who was successfully treated with anakinra (234 ). Other studies have since followed; in fact, King et al. have described ten ongoing clinical trials that target hyper-inflammation. It is clear that many different dosing regimens are being tested and that most of these smaller studies (<400 patients) should be considered preliminary, but data arising from these studies could lead to larger-scale studies with more uniform treatments. The outcomes of some of these anakinra studies have been published. In the anakinra-COVID study performed in France, 25% of patients who were treated with anakinra required invasive mechanical ventilation or died, compared to 44% of historical controls from the same hospital (235 ). In another small retrospective cohort study from Italy, part of the COVID-19 Biobank study, anakinra-treated patients showed improvement in respiratory parameters (reduced need of supplemental oxygen, improved PaO2/FiO2 ratio) and reductions in the inflammatory marker, C-reactive protein.
Lung inflammation caused by radiation can progress to fibrosis in later stages of injury, causing shortness of breath and reduced blood oxygen saturation. Drugs currently approved to treat lung fibrosis include nintedanib (OFEV®; Boehringer Ingelheim, Ingelheim am Rhein, Germany) and pirfenidone (Esbriet®; Genentech). Nintedanib is a tyrosine kinase inhibitor approved for idiopathic pulmonary fibrosis. Using a mouse model of localized irradiation, researchers demonstrated that nintedanib protected against long-term fibrosis, as detected microscopically at 39 weeks postirradiation (236 ). Similarly, studies showed protection in a mouse model of thoracic irradiation by pirfenidone treatment (237 ). In terms of COVID-19 and its progression, it was noted that patients who experienced severe ARDS often exhibit later lung fibrosis (238 ). Although anti-inflammatory treatments could prevent late-stage disease, it is not known if this will be the case for COVID-19. For this reason, the authors propose that anti-fibrotics, such as those described above, should be studied in clinical trials. In one clinical study (NCT04338802), patients will be randomized into a placebo-control or nintedanib treatment group, and in another, the safety and efficacy of pirfenidone will be studied in patients with SARS-CoV-2 infection (NCT04282902). Similarly, imatinib (Gleevec®; Novartis, Basel, Switzerland), licensed for chronic myeloid leukemia,10 and previously shown to increase the survival time of irradiated mice by delaying lung disease, has been suggested as a COVID-19 treatment (239 ). Several clinical trials are planned (NCT04357613) or recruiting (NCT04394416) patients to study the drug as a possible treatment for the disease.
Pentoxifylline is another drug that could potentially be repurposed as a treatment for COVID-19. Originally licensed to treat pain in individuals suffering from intermittent claudication (peripheral arterial disease),11 pentoxifylline improves blood flow, thereby increasing tissue oxygenation. It has also been shown to inhibit synthesis of pro-inflammatory cytokines, specifically TNF-α (240 ). Pentoxifylline has been shown to reduce radiation-induced fibrovascular injury in animal models (241 ) and in the clinic (242 ). Because of these anti-fibrotic (and anti-inflammatory) activities, pentoxifylline has been proposed as a possible preventative of COVID-19 complications (243 ) and will be tested in a clinical trial (NCT04433988). Another driver of pulmonary fibrosis, TGF-β (244 ), presents a potential target for the prevention of pulmonary fibrosis in COVID-19 patients (245 ). For example, an anti-sense mRNA product that targets TGF-β2 production, OT-101 (Mateon Therapeutics, San Francisco, CA), is in phase 3 trials for several cancers, and has been proposed as a COVID-19 treatment (246 ). Given the probable involvement of TGF-β in the progression of COVID-19, a preclinical, anti-TGFβ receptor 1 product, IPW5371 (Innovation Pathways, Palo Alto, CA) may also be a promising candidate to treat COVID-19-induced lung fibrosis, as it has previously been shown to reduce fibrosis and improve survival in a mouse model of radiation exposure (247 ).
In the early stages of the pandemic, it became clear that one method by which the SARS-CoV-2 virus gained access to the internal cellular machinery was via the ACE2 receptor, the expression of which is most prevalent on lung alveolar epithelial cells (248 ). This finding was similar to SARS-CoV, which also used the ACE2 receptor to gain entry into cells (249 ). Therefore, initial treatments considered for patients were angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type receptor blockers (ARBs). Because many drugs, such as angiotensin-converting enzyme inhibitors (ACEIs), are generic and widely available, they represent a valuable option in repurposed drugs. Clear benefits include low cost, wealth of clinical experience, established human data and minimal side effects. During the initial stages of the COVID-19 response, it was thought that individuals currently taking hypertensive drugs could be at an increased risk of infection, and therefore, their use should be discontinued in COVID-19 patients (250, 251 ). In one large retrospective study of over 12,000 patients, the relationship between prior use of ACEIs and patient outcomes after infection was considered, with the finding that there was no correlation between prior hypertension medication use and COVID-19 risk (252 ).
In addition, it became evident that certain segments of the population were more likely to have more severe forms of disease and a propensity to develop ARDS. These individuals included those with cardiovascular disease, diabetes and hypertension, all of which have associations with dysregulated aspects of RAS (253 ). Still other studies suggested that these drugs should be considered as a potential treatment due to their multi-prong effects (e.g., anti-inflammatory anti-oxidant and antifibrotic) (254 ). Therefore, there remains a need to evaluate both angiotensin agonists and antagonists for COVID-19 (255 ). In one study, COVID-19 patients with hypertension were enrolled, to explore if the use of ACEI or angiotensin receptor antagonist treatments would impact the severity and progression of the infection (256 ). As a biomarker of efficacy, serum levels of IL-6 and circulating T-cell counts were also evaluated. Both treatments were found to increase T cells, decrease viral load and IL-6 levels, and reduce the severity of the course of the disease. Therefore, the recommendation was made to maintain ACEI and angiotensin receptor blocker treatments in patients with COVID-19.
Similarly, the radiation community has established the role that products targeting RAS can play on the progression of radiation-induced organ injuries, primarily the lung and kidneys. Many studies have demonstrated the ability of ACEI products to address radiation-induced lung injuries. Primarily conducted in rat models of injury, ACEIs were found to increase survival and decrease lung, kidney and vascular damage (257, 258 ). These findings were consistent across different methods of radiation exposures, such as TBI plus bone marrow transplant (BMT), whole-thorax lung irradiation (WTLI), or partial-body irradiation (PBI) with a percentage of the bone marrow spared using shielding (259 ). Mitigation of lung and kidney injuries was determined through assessment of circulating markers of renal damage (e.g., blood urea nitrogen and creatinine) and CT imaging of lungs in irradiated animals. In an irradiated rat model, captopril and fosinopril both increased survival after 11 Gy (TBI with BMT) and decreased lung injury (257 ). Similarly, lisinopril was found to mitigate kidney (260 ) and lung (259 ) damage after high-dose PBI in adult rats and improve survival in juvenile and geriatric rats (38 ). Enalapril mitigated injury and improved survival in a WTLI rat model, even when initiated 35 days postirradiation (261 ). Captopril, administered in a TBI model, improved survival, although that benefit was diminished when coupled with skin trauma (262 ). Finally, ramipril mitigated radiation-induced damage to the spinal cord (263 ). In other preclinical models of radiation injury, angiotensin (1–7) [A(1–7)], a component of the RAS mentioned above, has also been studied for its ability to improve survival in irradiated rodents (264, 265 ). These peptides, which have been shown to alter activity in many cell types, accelerated recovery of the bone marrow in mice receiving TBI, and also improved the platelet nadir in the animals (264 ). In later studies, angiotensin peptides, even when administered days post-lethal irradiation, improved mouse survival and reduced bleeding time (265 ).
Approaches Targeting the Vasculature
The ability of the virus to directly infect and dysregulate endothelial cells (41 ) is the driving force behind vascular coagulopathies and thromboses observed in COVID-19 patients. In addition to vascular effects resulting from direct viral infection, COVID-19 patients have been found to have higher levels of VEGF as compared to healthy controls (266 ). Elevated VEGF could further increase vessel permeability, leading to some of the symptoms noted in patients. Furthermore, studies have implicated VEGF as a target for therapeutic intervention in ARDS (267 ). At the time of this writing, several clinical trials of COVID-19 patients are being planned or are recruiting to assess the potential efficacy of bevacizumab, an anti-VEGF, long-lived, humanized monoclonal antibody, as a treatment for COVID-19-associated ARDS (NCT04275414, NCT04344782, NCT04305106). Also known as Avastin®, the mechanism of action of the drug is to bind to extracellular VEGF and prevent its interaction with its receptor on endothelial cells (268 ).
Radiation exposure has long been known to lead to vascular impairment, which is believed to explain the multiorgan dysfunction that it causes (121 ). Many promising clinical approaches that target the vasculature could have an effect on radiation-induced damage. VEGF also represents a molecule that is involved in radiation exposure, and thus, is a target for reducing the negative effects. For example, VEGF levels have been shown to be increased in mice after irradiation (269, 270 ), and elevated levels of the growth factor have been implicated in the development of radiation-induced necrosis of normal tissue (271 ). Anti-VEGF antibodies (bevacizumab) have been shown to mitigate radiation necrosis in mouse brains (272 ), and in rats that underwent gamma-knife radiosurgery (273 ), and bevacizumab has been used in the clinic for radiation injury, where it was found to reduce necrosis in nasopharyngeal carcinoma patients who received radiotherapy (274 ).
As observations continue to be made in COVID-19 patients, it has become apparent that DIC may be responsible for many of the complications that have been seen (275–278 ). This condition, which is characterized by the development and circulation of small blood clots, can lead to the blockage of small vessels. As a follow-on effect, the abnormal consumption of platelets can, in turn, lead to thrombocytopenia and hemorrhage (279 ). In several animal models of lethal radiation exposure, including ferrets (280 ) and Yucatan minipigs (281 ), there has been evidence of DIC, both in the early days after irradiation and at the time of death. It is believed that DIC could be a contributor to radiation-induced human mortality (50 ), as hemorrhage at time of death has been seen clinically in irradiated patients. A major finding in autopsies of humans who have died from radiation exposure (282 ), widespread bleeding in the tissues often occurs as a result of DIC. Coagulation abnormalities have also clearly emerged as a key hallmark of COVID-19 infections (283 ). In addition to thromboses (284 ), thrombocytopenia has also been noted in some patients experiencing COVID-19 infection. In a study from China involving over 1,000 patients, 36.2% were thrombocytopenic, a finding that was greater in cases that were more advanced (98 ). This association of low platelet count with the infection is also supported by a meta-analysis in which data from nine studies were examined, involving nearly 1,800 patients (71 ). Those researchers found that platelet counts were much lower in patients with severe disease and concluded that these lowered counts could indicate an increased mortality risk. It is postulated that infection with SARS-CoV-2 leads to this dysregulated platelet state via a number of different causative pathways, including a reduction in platelet production due to loss of progenitors and growth inhibition, increased clearance due to evolution of autoantibodies, and enhanced platelet consumption due to lung injury, which leads to platelet activation and formation of microthrombi (284 ).
Like COVID-19, radiation exposures, especially TBI, are known to lead to a reduction in platelet levels. This thrombocytopenia has been postulated to play a major role in deaths from exposure (282 ). To address this manifestation of radiation injury, drugs that promote platelet production and are FDA-approved for other indications [e.g., immune thrombocytopenic purpura (ITP)] have been tested to see if they could mitigate damage and improve survival. This has included preclinical and clinical studies of drugs such as Nplate® (Amgen, Thousand Oaks, CA) (6, 285 ), and Promacta® (Novartis) (286, 287 ). Although there is a case report documenting use of Promacta to treat a COVID-19 patient who presented with ITP symptoms while hospitalized (288 ) and responded well to the treatment, it does not appear that these therapies have been attempted on a broader scale thus far. This may be due to the delicate balance between thrombocytopenia and thrombosis in these patients; timing of interventions is crucial to their efficacy or detriment. According to case reports, heparin has been administered as a means of countering hypercoagulation (289 ), and the International Society of Thrombosis and Haemostasis is now recommending use of heparin for all COVID-19 patients (290 ). Clearly, clinical decisions concerning the use of treatments that either enhance platelet counts or seek to reduce clotting are complex, and the use of these kinds of treatments represents an area of great interest. TP508, a 23 amino acid peptide that is a truncated form of human prothrombin, has also been shown to mitigate radiation normal tissue injury and increase survival in a mouse TBI (LD100/15) model (291 ). Under study in a number of other preclinical models [e.g., ischemia (292 ) and musculoskeletal injuries (293 ), and in clinical trials to address diabetic foot ulcers (294 )], TP508 has been shown to enhance tissue repair by targeting endothelial cells (292 ). This product is in early preclinical testing as a treatment for COVID-1912 because it targets the vasculature as its primary mechanism of action and has generalized ability to mitigate tissue damage.
Statins as a Common Treatment for Vascular Injury
Statins represent another area of drug treatment overlap between radiation and COVID-19 (295, 296 ). In addition to an anti-inflammatory effect, statins may modify the entry of viruses into cells, inducing autophagy of infected cells or altering activation of the coagulation cascade (297 ). In silico studies suggest that statins possess direct antiviral activity through blocking infectivity (298 ) and have been shown to enhance ACE2 levels (299 ) and protect against ARDS (300 ).
In clinical trials of COVID-19 patients, observed benefits were suggested to outweigh their potential risk (301 ). A retrospective study of patients treated with statins for other indications while hospitalized with COVID-19 showed a lower risk of mortality (302 ). In animal models of radiation injury, statins have demonstrated damage mitigation to normal tissues. Simvastatin, a HMG-CoA reductase inhibitor with widespread clinical use, has been shown to mitigate lung injury in a high-dose thoracic irradiation mouse model (303 ), and protects the GI tract, bone marrow (304 ) and salivary glands (305 ). Similarly, atorvastatin limits radiation-induced heart damage in a rat model (306 ) and kidney injury in mice (308 ).
Perhaps most significant, in terms of overlap with a primary mechanism of action involved in COVID-19, atorvastatin has been shown to induce a protective response in irradiated human umbilical vein endothelial cells (HUVECs) (308 ). Treatment of HUVECs with atorvastatin decreased radiation-induced cell apoptosis, thought to be driven by upregulation of thrombomodulin and protein C activation. Finally, lovastatin, when administered after high-dose irradiation in a WTLI mouse model, increased survival, reduced levels of macrophages and lymphocytes in the lung and decreased collagen (309 ). Activated protein C (APC) has been tested for its ability to mitigate radiation injuries (310 ) and has now been proposed as a therapy for the vascular dysfunction and abnormal thrombosis (e.g., DIC) observed in COVID-19 patients (311 ). APC's ability to downregulate inflammation and generate thrombin indicates its potential to reduce inflammation and limit ischemic injury throughout the body.
Antibiotic Treatments for Radiation or SARS-CoV-2 Infection, beyond Antibacterial Properties
Given the need to rapidly assess potential treatments, many clinicians have turned to antibiotics, which have the advantage of safety data and clinical experience. Several classes of antibiotics, which have activity against secondary bacterial infections and have anti-inflammatory and antiviral properties, have been suggested as potential treatments for COVID-19. In silico modeling and other predictive studies indicate efficacy of aminoglycoside compounds such as streptomycin (312 ); tetracyclines, such as doxycycline (313, 314 ) and eravacycline (312 ); macrolide antibiotics, such as azithromycin (315 ); streptogramins, such as quinupristin (316 ); polyether ionophoric antibiotics, such as salinomycin (317 ); and glycopeptides, such as teicoplanin. Teicoplanin, a drug used to treat Staphylococcus infections, was found to be effective against MERS and is predicted to also be effective against SARS-CoV-2 (318, 319 ). There was hope that azithromycin, in combination with hydroxychloroquine (320 ), might be effective in reducing the severity of SARS-CoV-2 infections (321 ). The drug, commonly used to treat respiratory and other infections, is thought to strengthen interferon-mediated antiviral responses (315 ). Unfortunately, clinical studies did not provide evidence of efficacy of the drug (322 ). In contrast, some studies suggest limited benefit from the use of antibiotics, either alone or in combination (323 ) in both children and adults with COVID-19 (324 ), and other research suggests that the use of some antibiotics could actually worsen the progression of the disease (325 ).
As with COVID-19, the efficacy of antibiotics, outside of their normal antibacterial impact, have been observed in the mitigation of radiation normal tissue injuries. In vitro screening of a broad range of antimicrobial agents was conducted to determine if any of these molecules could be used a mitigators of radiation injury. In one screen that used hematopoietic progenitor cells in a clonogenic survival assay, tetracycline was identified as a significant mitigator (326 ). In another in vitro screen of mouse lymphocytes, two antibiotic classes, tetracyclines and fluoroquinolones (10 different molecules), were identified as potential radiation mitigators, which the authors attributed to being separate from their antibacterial properties. From these potential mitigators, tetracycline showed efficacy in a TBI mouse model of survival and further data mining confirmed these earlier findings (327 ). The predicted impact of quinolones on mitigation of radiation injuries was not surprising, given earlier studies in mice that showed ciprofloxacin, sparfloxacin and clinafloxacin could enhance colony-forming units in the bone marrow and white blood cell counts in irradiated mice (328 ). Similarly, a published study from 1961 showed that the presence of chlortetracycline in rodent feed decreased X-ray killing in mice (329 ). In more recent studies, fluoroquinolones, such as ciprofloxacin and levofloxacin, as well as doxycycline, and neomycin, were all found to increase the mean survival time in mice exposed to lethal doses of radiation. Doxycycline and neomycin also improved day-30 survival in the animals (330 ). In other work, ciprofloxacin, an antibiotic notable for its efficacy in treating bacterial pneumonia and other infections, was also shown to enhance survival after radiation exposure in vivo and in vitro. In studies using peripheral blood mononuclear cells, ciprofloxacin protected against radiation exposure by inhibiting p53 phosphorylation and increasing Bcl-2 production (331 ), and has also been shown to increase survival in a mouse model of TBI (332 ).
The development and use of cellular therapies, in both the oncology clinic (333 ) and as a radiation treatment (334, 335 ), has long been an approach of interest. In particular, mesenchymal stem (or stromal) cells (MSCs) have been shown to mitigate the effects of radiation-induced lung injury (336, 337 ). Stem cells, as well as extracellular vesicles are also being considered as a means of treating injuries caused by SARS-CoV-2 (338 ). Specifically, MSCs derived from various sources, are under study to address lung injuries in COVID-19 patients (339 ). These sources include the bone marrow (340 ), umbilical cord (341 ), adipose tissue (342 ), peripheral blood and placenta. Early reported work indicates that the use of MSCs in patients is safe, and their use is effective in improving lung functional outcomes (343 ). There are more than 30 clinical trials worldwide in which these cells are being used as COVID-19 treatments (clinicaltrials.gov). In fact, several cellular therapies that are under active investigation for their development as radiation normal tissue injury mitigators are also showing promise as therapies in COVID-19 patient trials. These trials include those for placental expanded (PLX) cells13 and multipotent adult progenitor cells (Multi-Stem®; Athersys® Inc., Cleveland, OH).14
The majority of SARS-CoV-2 infections are asymptomatic or symptomatically mild and do not require hospitalization. However, at the time of this writing, there are over 50 million confirmed infections worldwide, with more than 9 million confirmed cases in the U.S. alone, of which hundreds of thousands have required hospitalization and over 225,000 have died. While host factors such as comorbidities, age and possibly genetics are strongly associated with the severity of disease, it is clear that the pathology of severe COVID-19 is characterized by a dysregulated inflammatory response, the so-called “cytokine storm,” along with a thrombotic response involving elevated D-dimer levels and coagulopathies ranging from small vessel thrombi to DIC. The cytokine storm is manifested through high levels of pro-inflammatory cytokines such as IL-1β, IL-6, IL-18, and TNFα. The cumulative systemic effects of the hyperinflammatory response and dysregulated thrombotic activity can lead to multi-organ failure and death. In the current absence of any effective prophylactic interventions, therapeutics capable of beneficially altering these dysregulated processes and supporting recovery are urgently needed.
A striking feature of the immune dysregulation, progression of disease and mechanisms of organ damage in COVID-19 is its similarity to the biological responses to ionizing radiation exposure at doses sufficiently large to cause ARS (>2 Gy in humans). The similarity of inflammatory responses and organ damages that are caused by COVID-19 and radiation offers an opportunity for possible COVID-19 interventions. There is a wealth of data (detailed above) and extensive experience from the field of radiation biology for the development of radiation mitigators that target radiation-induced dysregulation of inflammation, lung fibrosis and vascular damage that may lead to multi-organ failure and death in a fashion similar to that seen in COVID-19. Many of these agents are currently at preclinical levels of development, but several are already licensed as radiation mitigators and FDA approved for use in humans (Neupogen®, Neulasta®, Leukine®), or have demonstrated safety in human clinical trials for other indications, and are therefore well-poised for possible translation to COVID-19 indications. Finally, in perhaps the truest definition of overlap between radiation and COVID-19, is the novel (and yet “old-school”) proposal, that low-dose radiation therapy (LDRT), involving exposure of the thorax of the patient, may have efficacy in countering lung infections, including those caused by SARS-CoV-2 infection. This concept is based on studies on the use of radiation exposures in the early 1900s, before the advent of modern antibiotics, in which radiation was used to treat pneumonias resulting from bacterial or viral infections (344 ). This treatment proposal, however, is not without controversy. Already, numerous editorials and comments have been published (345–352 ) and discussion surrounding this treatment modality will undoubtedly continue. Nonetheless, LDRT is not considered to be a potential mitigator of high-dose radiation damage to the lung, and therefore this treatment generally falls outside the scope of the current review.
While medical expertise in the fields of infectious disease, pulmonology, immunology, rheumatology and hematology are critical paths forward in the search for COVID-19 therapeutic interventions, the substantial overlap in pathobiology between COVID-19 and ARS presents the possibility of readily translatable, potentially high-impact pharmacological interventions that were originally evaluated and/or developed to mitigate radiation injury in humans. By the same token, it is possible that, given the broad range of new treatment approaches that are being considered for possible efficacy in COVID-19 infections, some of these could one day be repurposed for use as radiation medical countermeasures.
A friend and colleague of the NIAID, Col. (ret.) and Dr. David Barillo sadly passed away due to complications from COVID 19 on August 11, 2020. David was an important mentor and voice in the community in the area of cutaneous radiation injuries (as the Medical Director of Argentum), due in part to his career devoted to the care of combat casualties, and as a lead burn surgeon. His great personality, passion for science and dedication to saving lives will be missed by all who were fortunate enough to know him.
2 NIAID strategic plan for COVID-19 research FY2020–FY2024, April 22, 2020. (https://bit.ly/3mFnb2e)
3 NIH/National Cancer Institute. NCI Dictionaries. Cytokine storm. (https://bit.ly/35RIp73)
4 U.S. Food and Drug Administration. Letter to Linda McCammack, Senior Regulations Manager, Roche Diagnostics. Emergency use authorization for Elecsys IL-6. June 2, 2020. (https://bit.ly/32NzWzG)
5 U.S. Dept. of Health and Human Services. REMM/Radiation Emergency Medical Management. Guidance on diagnosis and treatment for healthcare providers. (https://www.remm.nlm.gov/)
6 U.S. Food and Drug Administration. In vitro diagnostics EUAs. (https://bit.ly/3mEFODt)
7 NIH/U.S. National Library of Medicine. ClinicalTrials.gov. (https://clinicaltrials.gov/)
8 Saey TH. A popular heartburn medicine doesn't work as a COVID-19 antiviral. ScienceNews 2020. (https://bit.ly/2ZSFtDi)
9 RECOVERY/Randomised Evaluation of COVID-19 Therapy. Oxford, UK: University of Oxford; 2020. (https://www.recoverytrial.net/)
10 Gleevec (imatinib mesylate) tablets for oral use. Prescribing information. Stein, Switzerland: Novartis Pharma Stein AG; East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2008. (https://bit.ly/3kyuqan)
11 Trental® (pentoxifylline). Reference ID: 3873773. Parsippany, NJ: Validus Pharmaceuticals LLC; 2016. (https://bit.ly/2ZYT6Rz)
12 Chrysalis BioTherapeutics receives funding from the National Institutes of Health for COVID-19 therapeutic development. Galveston, TX: Chrysalis BioTherapeutics Inc.; 2020. (https://bit.ly/2HkvCQm)
13 Pluristem provides 28-day follow up for ventilator-dependent COVID-19 patients under compassionate use program in Israel and U.S. Los Angeles, CA: GlobeNewswire, Inc.; 2020. (https://bit.ly/3cjdzVX)
14 COVID-19 and other viral induced ARDS. Cleveland, OH: Athersys®, Inc.: 2020. (https://bit.ly/33IsQMe)